Cabergoline in prolactinomas

Cabergoline is a potent, D2-selective new dopamine agonist with a half-life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better toler ated than bromocriptine, compliance may be improved, and costs are comparab le, In cases of bromocriptine failure, unusually high starting doses of cab ergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.